Fluconazole
Active ingredient · 2 therapeutic classes
Sold as AZOCAN-P · DIFLUCAN · MONICURE · CANESORAL · DIFLUCAN ONE
- Drug class
- Triazole and Tetrazole Derivatives
- Availability
- Prescription only
- Routes
- Oral, Intravenous
- Markets covered
- 3
- Products on record
- 115
- FDA reports (12 mo)
- 3,411
Overview
Plain-language summary, compiled from the cited regulatory records
Fluconazole is an antifungal medication belonging to the imidazole and triazole derivative class [1]. It is approved for the treatment of vaginal candidiasis (yeast infections) [1]. Fluconazole is also indicated for oropharyngeal and esophageal candidiasis [1]. In clinical studies, it has shown effectiveness in treating Candida urinary tract infections, peritonitis, and systemic Candida infections, including candidemia, disseminated candidiasis, and pneumonia [1]. Additionally, it is used for cryptococcal meningitis [1].
Fluconazole is available in the market under various brand names [1]. In the past 12 months, there have been 3,411 adverse event reports associated with fluconazole [2]. The most frequently reported events include off-label use, drug ineffectiveness, headache, nausea, and pyrexia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 63 | May 22, 2026 |
| CA Canada | Health Canada | 39 | February 18, 2026 |
| US United States | FDA | 13 | March 19, 2026 |
GBUnited Kingdom· MHRA
63 products
Uses
Fluconazole is indicated for the treatment of the following infections when caused by fungi that are known or likely to be fluconazole-susceptible: acute or recurrent vaginal candidiasis.
How to take
CACanada· Health Canada
39 products
Uses
CANESORAL® (fluconazole capsule) is indicated for the single-dose treatment of vaginal candidiasis (yeast infections due to Candida) and is clinically proven to cure most vaginal yeast infections. CANESORAL® COMBI 1 DAY contains CANESORAL® (fluconazole capsule) and CANESTEN® EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAM (clotrimazole 2%) which is indicated for the topical treatment of external irritation caused by vulvovaginal candidiasis.
1 Pediatrics Pediatrics (>12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CANESORAL® and CANESORAL® COMBI 1 DAY in pediatric patients has been established. 3 Pediatrics).
How to take
USUnited States· FDA
13 products
Uses
INDICATIONS AND USAGE
Fluconazole tablets are indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida ) 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia.
3. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted.
Prophylaxis:
Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms.
Drug interactions
Known interactions involving Fluconazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL203950042 · revised May 22, 2026
- [2]Health Canada (DPD) · 02311690 · revised February 18, 2026
- [3]FDA DailyMed · 13184b13-e252-4b… · revised March 19, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.